Physician profile
Barbara S Craft
NPI 1104862259
$11,424.95
in general payments reported to CMS, 2019-2025
75 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $525 · 2021: $1,047 · 2022: $804 · 2023: $1,823 · 2024: $2,559 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,290 · Education: $6.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,289.55 |
| Education | $6.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $854.87 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Gilead Sciences, INC. | $845.68 | 2021-2025 | Trodelvy |
| Pfizer INC. | $666.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $562.06 | 2019-2025 | |
| Daiichi Sankyo INC. | $561.77 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Janssen Biotech, INC. | $557.07 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $437.81 | 2019-2025 | Jakafi, Monjuvi |
| Amgen INC. | $408.36 | 2019-2023 | Lumakras |
| Astellas Pharma US INC | $402.63 | 2019-2025 | Xospata, Cresemba, Xtandi |
| Puma Biotechnology, INC. | $402.31 | 2019-2025 | Nerlynx |
| Merck Sharp & Dohme LLC | $396.88 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $363.25 | 2019-2025 | Reblozyl, Breyanzi, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $328.94 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Genentech USA, INC. | $262.70 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Abbvie INC. | $226.59 | 2019-2025 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.